Related Experiment Video
Updated: May 12, 2026
Methods to Evaluate Cytotoxicity and Immunosuppression of Combustible Tobacco Product Preparations
Published on: January 10, 2015
Association Between Smokeless Tobacco Use and Cardiovascular Disease Outcomes: A Systematic Review and Meta-Analysis
Muhammad Usman Khan1, Maria Sultana2, Julia Natche3
1Internal Medicine, Cumberland Infirmary, Carlisle, GBR.
Background:
Smokeless tobacco (SLT) use remains prevalent globally and is associated with cardiovascular disease (CVD). However, variations in product composition, particularly between Scandinavian snus and alkaline, unfermented preparations such as Nawar, may influence risk profiles.
Methods:
We conducted a systematic review and meta-analysis following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines. PubMed/MEDLINE, EMBASE, Web of Science, and Cochrane Central Register of Controlled Trials (CENTRAL) were searched from January 1990 to December 2024 (final search: December 15, 2024). Observational studies evaluating SLT use and CVD outcomes in adults were included. Sixteen studies met the inclusion criteria, including 14 primary studies and 2 prior meta-analyses. Random-effects models were used to compute pooled odds ratios (ORs). Primary outcomes included composite CVD events (fatal and non-fatal), myocardial infarction (MI), stroke, and CVD mortality.
Results:
SLT use was associated with increased CVD risk (pooled OR: 1.45; 95% CI: 1.28-1.64; I² = 47%). Elevated risks were observed for MI (OR: 1.42; 95% CI: 1.21-1.67) and composite CVD outcomes (OR: 1.61; 95% CI: 1.32-1.96). Subgroup analyses showed higher estimates in South and Central Asia (OR: 1.83), though these were based on a limited number of studies. Nawar-type products were represented in a small subset of studies, and their contribution to the pooled estimate was limited relative to mixed SLT and Scandinavian snus cohorts. Sensitivity analyses excluding prior meta-analyses yielded consistent but slightly attenuated estimates.
Conclusions:
SLT use is associated with a statistically significant increase in CVD risk. While Nawar-type products may confer a higher risk, evidence remains limited and predominantly derived from cross-sectional studies. Large prospective studies in high-prevalence regions are required to clarify product-specific effects.
Related Concept Videos
01:29Stimulants
Cocaine can be administered via snorting, injection, or smoking. It primarily functions by blocking the reuptake of dopamine, resulting in a euphoric high characterized by an intense sensation of happiness and...
01:25Statistical Methods for Analyzing Epidemiological Data
01:23Drugs Acting on Autonomic Ganglia: Stimulants
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating sympathetic or...
01:26Atherosclerosis III: Management
01:11Observational Studies
There are three types of observational studies – Prospective, retrospective, and cross-sectional.
Prospective Study
Prospective studies, also known as longitudinal or cohort studies, are carried out by collecting future data from groups sharing similar characteristics. One example of...
01:23Assessment of the Cardiovascular System I: Subjective Data
Initial Enquiry
Ask the patient about their primary concern and thoroughly explore all reported symptoms.
Medical History
Investigate past illnesses affecting the cardiovascular system, such as angina, anemia, rheumatic fever, congenital heart disease, stroke, thrombophlebitis, dysrhythmias, varicosities
Inquire about symptoms...